Viridian Therapeutics, Inc. (NASDAQ:VRDN) COO Acquires $117,050.00 in Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) COO Thomas W. Beetham bought 5,000 shares of the business’s stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the acquisition, the chief operating officer now directly owns 6,000 shares of the company’s stock, valued at approximately $140,460. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Viridian Therapeutics Trading Up 2.7 %

Shares of NASDAQ VRDN opened at $24.25 on Thursday. The firm’s 50 day moving average price is $17.48 and its 200-day moving average price is $15.35. Viridian Therapeutics, Inc. has a 52-week low of $10.93 and a 52-week high of $24.68. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.82 and a current ratio of 15.82. The company has a market cap of $1.55 billion, a PE ratio of -5.39 and a beta of 1.03.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.15). Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. The business had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.09 million. On average, equities research analysts expect that Viridian Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on VRDN. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, September 10th. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 target price (down from $31.00) on shares of Viridian Therapeutics in a research report on Monday, August 12th. Needham & Company LLC upped their target price on Viridian Therapeutics from $30.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. The Goldman Sachs Group raised their target price on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Thursday, September 19th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.80.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VRDN. Ameritas Investment Partners Inc. grew its holdings in shares of Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after acquiring an additional 799 shares during the period. Principal Financial Group Inc. lifted its position in shares of Viridian Therapeutics by 9.7% in the first quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after buying an additional 1,058 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Viridian Therapeutics by 4.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock worth $505,000 after buying an additional 1,135 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Viridian Therapeutics by 14.7% in the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after buying an additional 1,688 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after buying an additional 2,359 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.